CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Natalizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03046251
NCT03046251Phase 4Completed
CompareCT.gov

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

State University of New York at Buffalo·interventional·Posted Feb 8, 2017·Updated Jan 24, 2025

In Brief

A Phase 4 clinical trial evaluating Natalizumab for Multiple Sclerosis. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 8, 2017
Enrollment StartAug 1, 2015
Primary CompletionDec 1, 2023
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 9.4 years ago

Interventions

Natalizumabdrug